The G protein-coupled estrogen receptor (GPR30) is suggested to exert a role in non-nuclear estrogen signalling and is over-expressed in a variety of hormone dependent cancer entities. It is well established that oestrogens are involved in testicular germ cell tumours. In a recent paper published in Journal of Cellular Physiology, we show that down regulation of estrogen receptor β (ERβ) associates with GPR30 over-expression both in human testicular carcinoma in situ (CIS) and seminomas. In addition, we demonstrate that 17-oestradiol induces the ERK1/2 activation through GPR30. The results suggested that exposure to oestrogens or oestrogen-mimics, in some as of yet undefined manner, diminishes the ER-mediated growth restraint in CIS and in human testicular seminoma, indicating that GPR30 could be a potential therapeutic target to design specific inhibitors.
GPR30 mediates estrogenic signals
The estrogen receptor β (ER) subtype is the principal mediator of oestrogen action in promoting germ cell survival and development [1] [2] [3] [4] . After activation, these receptors, in association with various coactivators as RNF4 [5, 6] and repressors as PATZ1 [7] [8] [9] [10] , act as nuclear transcription factors for targeted genes [11] . It has been well documented in literature that ER is instead down regulated in seminomas and embryonal cell carcinomas [7, 12, 13] . In the last few years, G protein-coupled receptor 30 (GPR30) was demonstrated to be capable of mediating estrogen actions in a wide variety of cell types including germ cells and Sertoli cells [13] [14] [15] ; GPR30 has been recently found to bind 17β-estradiol (E2) with high affinity and to mediate estrogenic signals [16, 17] controlling the proliferative effects of E2 in ER-negative SKBr3 breast cancer cell lines since GPR30 depletion, by using antisense oligonucleotides or RNA interference (RNAi) strategies, abrogated E2-stimulated growth in these cells [17] . GPR30 activates numerous cell signaling pathways including calcium mobilization, adenylyl cyclase, MAP kinase and phosphatidyl inositol 3-kinase, in large part via the transactivation of epidermal growth factor receptors (EGFRs) [18, 19] . These observations led to the hypothesis that GPR30 activation may represent an alternative pathway for estrogen-mediated activity in high grade and advanced stage in various epithelial tumors that are more often ER negative.
GPR30 is a potential therapeutic target
Our recent published study was the first that correlates the GPR30, and ER expression in testicular human carcinoma in situ (CIS) and seminomas [20] . First, the down-regulation of ER, observed in seminomas, was in accordance with our previously published data, and from animal models and human cell culture studies suggesting that ER may control cell proliferation during germ cells cancer progression [7, 8, [21] [22] [23] [24] . These considerations induce to hypothesize that
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exposure to estrogens, in some as of yet undefined manner, diminishes the ER-mediated growth restraint in spermatagonia, which favors unscheduled cell proliferation. The affected spermatogonia or their descendants may then be able to escape normal cell cycle regulation and be at a higher risk of undergoing malignant transformation [8] .
Recently, we have shown that ER interacts with HMGA1 and PATZ1 in normal germ cells, while down regulation of ERβ is concomitant with transcriptional coregulators HMGA1 and PATZ1 over-expression and cytoplasmic localization both in human testicular seminomas and in TCam-2 seminoma cell line [7] [8] [9] [10] . We also observed that 17-oestradiol induces an HMGA1 increased cytoplasmic expression correlates with an ER down-regulation in TCam2 cell line [8] .
In addition, our group has published that GPR30 is over-expressed in human testicular seminomas, which are more often ERα/β negative [8, 15, 25] .
The relationship between estrogen signaling and its multiple regulatory interactions with growth factor and other kinase signaling pathways involves complex patterns of genomic and non-genomic cross-talk. Estrogen, as well as many of the classic ER antagonists and estrogen receptor modulators (SERMs, including fulvestrant and tamoxifen) activate signaling pathways via GPR30 [16, 17, 26] . In addition, in our recent published study we have shown by using the TCam2 seminoma cell line that 17β-estradiol induces ERK1/2 activation and c-fos increased expression in absence of ER and in presence of GPR30 [20] . Studies that evaluate GPR30 expression in relation to the classical steroid receptors (ERα/β, PR) and response to chemotherapy are needed to elucidate the value of GPR30 as a prognostic indicator [8, 15, 27] . Since many G protein-coupled receptors, including GPR30, induce EGFR phosphorylation, the inter-receptor cross-talk demonstrated by this paradigm represents a novel opportunity for therapeutic intervention [28] . Therefore, the expression or function of GPR30 with selective agonists [29] and/or antagonists [30] could be an effective treatment strategy, in conjunction with standard chemotherapy [8, 15, 27] . In fact, we have demonstrated that G15, a new selective GPR30 antagonist, inhibits estrogen-induced proliferation in TCam2 seminoma cell line [20, 31, 32] .
In conclusion, the design of specific GPR30 inhibitors could represent a useful molecular target to block neoplastic germ cells with a high proliferative rate suggesting its potential therapeutic role for the treatment of CIS and seminomas.
